Impact of Reduced Vancomycin MIC on Clinical Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia

Vancomycin has been a key antibiotic agent for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. However, little is known about the relationship between vancomycin MIC values at the higher end of the susceptibility range and clinical outcomes. The aim of this study was...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Park, So-Youn, Oh, In-Hwan, Lee, Hee-Joo, Ihm, Chun-Gyoo, Son, Jun Seong, Lee, Mi Suk, Kim, Mi-Na
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2013
Assuntos:
Susceptibility
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3811271/
https://ncbi.nlm.nih.gov/pubmed/23979741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01137-13
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares